Patients with metastatic CRC may not need removal of asymptomatic colon tumor

Despite better screening for colorectal cancer (CRC), about 1 in 5 newly diagnosed patients will have metastatic CRC that already has spread to distant organs.  Many will have symptoms of fatigue or weight loss, but only a minority will have symptoms (significant bleeding or abdominal pain, or a blocked bowel) caused by the colon tumor itself.…  Read More

Ziv-Aflibercept gets FDA approval

Ziv-Aflibercept Approved as 2nd line treatment for metastatic CRC   For the first time in more than five years, the FDA has approved a new drug for certain patients who have metastatic colorectal cancer. The FDA has approved ZALTRAP® (ziv-aflibercept) to be used with FOLFIRI as a “second-line” treatment for patients with stage IV colorectal cancer whose…  Read More

Avastin Helps Patients Maintain Chemotherapy Effectiveness

It doesn’t hurt to stop XELOX chemotherapy combined with Avastin after six treatments and continue with Avastin alone until colorectal cancer gets worse, according to a study reported at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. Many patients have to stop oxaliplatin chemotherapy with before getting its maximum effectiveness because…  Read More

Hedgehog Fails to Help Advanced Colorectal Cancer Patients

In disappointing news, adding the Hedgehog inhibitor GDC-0449 to standard chemotherapy failed to increase the time before advanced colorectal cancer got worse. Researchers compared progression-free survival between patients who got either FOLFOX or FOLFIRI chemotherapy with Avastin and a group who got the same chemo regimen with GDC-0449. There was no difference

Adding Erbitux to First Line Chemotherapy Helps Advanced Colorectal Cancer Patients with Wild Type KRAS

Does adding Erbitux to chemotherapy help people whose colorectal cancer has spread beyond the colon or rectum to distant body sites? The answer is yes, according to a pooled analysis of two large randomized clinical trials comparing chemotherapy alone to chemotherapy plus Erbitux® (cetuximab).  However, benefits depend on whether or not patient tumors have mutations of…  Read More

Young People with Advanced Colorectal Cancer Do As Well with Chemotherapy as Older Patients

When colorectal cancer spreads to other parts of the body, young people under 50 who get chemotherapy benefit as much as those who are older. With drug combinations, there is no difference between those under 50 and those who are 50 and older in responding to chemotherapy, how long it takes before cancer gets worse, or…  Read More